Literature DB >> 7925562

Major histocompatibility complex regulation of T helper functions mapped to a peptide C terminus that controls ligand density.

J S Murray1, D Ferrandis-Edwards, C J Wolfe, T Schountz.   

Abstract

The functional status (Th1- versus Th2-like) of CD4 T cells primed against human collagen type IV (hCol IV) or a single 30mer peptide from the alpha 2 chain of this molecule is predicted by the major histocompatibility complex (MHC) class II (I-A) genotype of the responding mice. H-2s mice elicit Th1-like cell-mediated responses to these antigens, whereas Th2-like humoral responses are primed in H-2b,d,k mice. We now report that the ability of MHC to dictate T helper function in this system depends upon a single amino acid of the minimal alpha 2(IV) peptide. The C terminus of this minimal (12mer) peptide is -G-G-P-K, which is predicted to form a beta-turn. The present data demonstrate that the terminal lysine (K) stabilizes the immunogens full biological effects necessary for exclusive cell-mediated responses in H-2s mice. The lysine-truncated (11mer) peptide with otherwise identical sequence effectively primes T helper function in both H-2b and H-2s genotypes. Most importantly, our direct analysis of these peptides' presentation by live antigen-presenting cells (APC) reveals that the 12mer is bound at a log higher density on H-2s APC than on H-2b APC, and that the 11mer is presented at an equally low relative density on APC from both genotypes. In vitro analyses of 12mer/11mer cross-reactive Th clones demonstrate that I-As restricted clones require about 1-2 log lower doses of 12mer peptide than 11mer peptide to stimulate equivalent thymidine incorporation and cytokine release. By contrast, I-Ab-restricted (12mer/11mer cross-reactive) Th clones show no preference for the 12mer and require relatively high peptide doses similar to those required to stimulate the I-As clones with the 11mer peptide. Thus, the peptide dose requirements of Th clones reflect the high density of presentation associated with the 12mer: I-As ligand. Taken together, the results directly support the role of ligand density as an important control point in the functional decision of CD4 T cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7925562     DOI: 10.1002/eji.1830241012

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  6 in total

1.  Major histocompatibility complex controls the trajectory but not host-specific adaptation during virulence evolution of the pathogenic fungus Cryptococcus neoformans.

Authors:  Erin E McClelland; Frederick R Adler; Donald L Granger; Wayne K Potts
Journal:  Proc Biol Sci       Date:  2004-08-07       Impact factor: 5.349

2.  Altered peptide ligands can modify the Th2 T cell response to the immunodominant 161-175 peptide of LACK (Leishmania homolog for the receptor of activated C kinase).

Authors:  Kirk D C Jensen; Eli E Sercarz; Claudia Raja Gabaglia
Journal:  Mol Immunol       Date:  2008-11-29       Impact factor: 4.407

3.  Extending the CD4(+) T-cell epitope specificity of the Th1 immune response to an antigen using a Salmonella enterica serovar typhimurium delivery vehicle.

Authors:  R Lo-Man; J P Langeveld; E Dériaud; M Jehanno; M Rojas; J M Clément; R H Meloen; M Hofnung; C Leclerc
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

4.  Role of individual T-cell epitopes of Theiler's virus in the pathogenesis of demyelination correlates with the ability to induce a Th1 response.

Authors:  R L Yauch; J P Palma; H Yahikozawa; C S Koh; B S Kim
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

5.  Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus.

Authors:  P W Tebbey; M Hagen; G E Hancock
Journal:  J Exp Med       Date:  1998-11-16       Impact factor: 14.307

6.  Generation of competent bone marrow-derived antigen presenting cells from the deer mouse (Peromyscus maniculatus).

Authors:  Bennett J Davenport; Derall G Willis; Joseph Prescott; Regina M Farrell; Teresa A Coons; Tony Schountz
Journal:  BMC Immunol       Date:  2004-09-30       Impact factor: 3.615

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.